PARP1 and ovarian carcinoma: Innovative treatment of epithelial ovarian cancer with PARP inhibitors (PARPis) has shown excellent effectiveness, plays a vital role in the treatment of newly diagnosed ovarian cancer, and is changing clinical practice in patients with BRCA mutations.41, 42